Royalty Report: Drugs, Cancer, Drug Discovery – Collection: 308740


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 10


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10

Primary Industries

  • Drugs
  • Cancer
  • Drug Discovery
  • Stem cells
  • cell therapy
  • Biotechnology
  • Disease
  • Antibody
  • Therapeutic
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 308740

License Grant
Licensor, a non-profit corporation,  hereby grants to Licensee an exclusive (even as to Licensor) royalty-bearing sublicensable license under Licensor Technology to make, have made, manufacture, have manufactured, formulate, use, have used, sell, offer for sale, have sold, import, export, research, develop, have developed, register, transport, distribute, promote, market or otherwise dispose or offer to dispose of Compounds and/or Licensed Products or in the Field in the Territory.  Licensee hereby grants Licensor a nonexclusive, non-sublicensable, royalty-free sublicense under the license granted to Licensor pursuant to the preceding sentence during the Research Term solely to the extent necessary to conduct the Research Program in accordance with this Agreement.
License Property
Compound shall mean Interleukin-3/Diphtheria Toxin recombinant peptide-toxin conjugate  DT388IL3, DT388K116W and any improvements thereof.

SL-401 is a clinically active biologic-drug conjugate comprised of human interleukin-3 (IL-3) genetically linked to a truncated version of diphtheria toxin. SL-401 targets the IL-3 receptor, or IL-3R, which is overexpressed on both the CSCs and tumor bulk of multiple hematologic cancers, including AML. In contrast, IL-3R is not expressed on normal bone marrow stem cells that form the components of blood. SL-401 demonstrated single agent anti-tumor activity in a completed Phase 1/2 clinical trial of 76 patients with advanced hematologic cancers, including 57 patients with relapsed or refractory AML. With only a single cycle of treatment, SL-401 induced either a reduction in leukemia blasts (i.e., tumor bulk) or disease stabilization in 47% (27/57) of relapsed or refractory AML patients.

This compound is being developed to treat patients with AML and other hematologic cancers.

U.S. Provisional Application No. 60/843,471
U.S. Provisional Application No. 60/932,772
U.S. Non-Provisional Application No. 11/899,747
U.S. Non-Provisional Application No. 12/368,048

Field of Use
The lead indication for SL-401, a biologic-drug conjugate, is acute myeloid leukemia, or AML.

IPSCIO Record ID: 7534

License Grant
Israeli Licensor hereby grants to Israeli Licensee an exclusive, royalty-bearing, worldwide license under Licensor’s rights in the Licensed Technology to research, have researched, develop, have developed, manufacture, have manufactured, use, market, distribute, offer for sale, sell, have sold, export and import Licensed Products and/or provide services relating thereto.
License Property
“Drug” means 4F-benzoyl- TN14003.

BL-8040 (formerly BKT-140) is for the treatment of acute myeloid leukemia, as well as other types of hematological cancer (the “Drug”).

BL-8040, is a novel short peptide that functions as a high-affinity antagonist for CXCR4, which we intend to develop for AML, and other hematological indications. BL-8040 mobilizes cancer cells from the bone marrow and may therefore sensitize these cells to chemo- and bio-based anti-cancer therapy. In addition, BL-8040 has demonstrated a direct anti-cancer effect by inducing apoptosis (cell death). Multiple pre-clinical studies have shown the safety and efficacy of BL-8040. BL-8040 also mobilizes stem cells from the bone marrow to the peripheral blood, enabling their collection for subsequent autologous or allogeneic transplantation in cancer patients.

Field of Use
BL-8040 is a novel peptide for the treatment of acute myeloid leukemia and other hematological indications.

IPSCIO Record ID: 259856

License Grant
Licensor grants an exclusive sublicense even as to Licensor under the Sublicensed Subject Matter to research, develop, manufacture, have manufactured, use, import, offer to sell and/or sell Sublicensed Products within the Sublicensed Territory for use within the Sublicensed Field.
License Property
The grant is for certain intellectual property rights, including rights to Annamycin, Licensors WP1122 portfolio, and WP1066 portfolio in the field of non-human animals.

Annamycin is an anthracycline antibiotic being investigated for the treatment of cancer.

Field of Use
The Sublicensed Field means the use of Licensed Product for the treatment of cancer in non-human animals through any type of administration.

Licensor is a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on discoveries made at M.D. Anderson Cancer Center. The Licensor's clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML.

IPSCIO Record ID: 319042

License Grant
Licensor and Hong Kong Licensee agreed to collaborate for the development and commercialization of uproleselan and GMI-1687 in Mainland China, Hong Kong, Macau and Taiwan, also known as Greater China and to advance the preclinical and clinical development of GMI-1687.
License Property
GMI-1687 is a potential life-cycle extension to uproleselan that has been designed as an innovative antagonist of E-selectin that could be suitable for subcutaneous administration.

Uproleselan is a glycomimetic drug candidate and a specific E-selectin inhibitor that is being developed to be used in combination with chemotherapy to treat patients with acute myeloid leukemia, or AML, a life-threatening hematologic cancer, and potentially other hematologic cancers.

E-selectin plays a critical role in binding cancer cells within vascular niches in the bone marrow, which prevents the cells from entering the circulation where they can be more readily killed by chemotherapy.  Glycomimetics are molecules that mimic the structure of carbohydrates involved in biological processes.

Field of Use
The field of use is for the treatment in combination with chemotherapy to treat patients with acute myeloid leukemia (AML) and potentially other hematologic cancers.

IPSCIO Record ID: 360156

License Grant
Swss Licensor provided Licensee with a royalty-bearing license (with the right to grant sublicenses through multiple tiers) to utilize patents and know-how to conduct research and to develop, make, use or offer for sale products developed from certain single chain fragment variable compounds known as DLX105 and DLX2751 owned by the Licensor.
License Property
DLX105 and DLX2751 means antibody therapies of various formats including single chain Fv fragments (scFv), IgG and bispecific antibodies.
Field of Use
Field of use is for the treatment for the treatment of solid and hematological malignancies.

Hematologic malignancies are cancers that affect the blood, bone marrow, and lymph nodes. This classification includes various types of leukemia (acute lymphocytic (ALL), chronic lymphocytic (CLL), acute myeloid (AML), chronic myeloid (CML)), myeloma, and lymphoma (Hodgkin's and non-Hodgkin's (NHL)).

IPSCIO Record ID: 336338

License Grant
Licensor, a non-profit health care organization, grants to Licensee the worldwide and exclusive license with a right to sublicense, under the Patent Rights, to make, have made, use, have used, offer for sale, have offered for sale, import, have imported, have sold and sell the Licensed Products, and to practice the Licensed Processes, in the Territory for the Field of Use to the end of the Term, unless sooner terminated as provided in this Agreement.
License Property
Rights relate to therapeutic compositions of modulated HSCs and methods for promoting reconstitution of the hematopoietic system using modulators of the prostaglandin pathway.

Licensor is the co-owner with a Hospital Corporation of certain Patent Rights.  The patents are Method to Modulate Hematopoietic Stem Cell Growth, and, Method to Enhance Tissue Regeneration.

ZON IND shall mean the investigational new drug application titled A Phase I Study of Reduced Intensity, Sequential Double Umbilical Cord Blood Transplantation Using Ex-Vivo 16,16 Dimethyl-Prostaglandin E2 Expanded Umbilical Cord Blood Units.

Field of Use
Licensee's HSC modulation platform focuses on the ex vivo pharmacologic optimization of hematopoietic stem cells, or HSCs, which are adult stem cells that regenerate all types of blood cells throughout a person’s lifespan. HSCs have been used for decades in a potentially curative procedure called hematopoietic stem cell transplant, or HSCT. This procedure is most commonly used in patients with hematologic malignancies to replace a diseased hematopoietic system with a healthy one. While over one million HSCT procedures have been performed to date, we believe HSCs have not been pharmacologically optimized to improve patient outcomes. Licensee'sHSC modulation platform has the potential to generate products that will improve patient outcomes in orphan indications by enhancing hematopoietic reconstitution through accelerated, durable engraftment, permitting greater donor matching flexibility, reducing the risk of major side effects and enabling the use of less toxic conditioning regimens.

Licensee's lead product candidate, ProHema, is a pharmacologically modulated HSC therapeutic derived from umbilical cord blood. Licensee has established human proof-of-concept for ProHema in the clinical setting by demonstrating enhanced and durable engraftment of HSCs within the bone marrow. Engraftment, which is the localization and integration of HSCs within a targeted tissue where they can produce new cells, is an important determinant of patient outcomes in HSCT. Licensee is presently advancing ProHema in Phase 2 clinical development for hematologic malignancies. Licensee is also pursuing the development of pharmacologically optimized HSC therapeutics for the treatment of certain lysosomal storage disorders, or LSDs, where HSCs have demonstrated the ability to home, or migrate, to and engraft within the central nervous system, or CNS.

IPSCIO Record ID: 362432

License Grant
Licensor grants an exclusive license, including the right to grant sublicenses, under the Licensed Patent Rights and Licensed Technology and Licensors interest in any Improvements, subject at all times to the restrictions and obligations under a Stanford Agreement with respect to the Stanford IP, to research, develop, test, obtain Regulatory Approval for, make, have made, use, have used, sell, offer for sale, have sold, import, have imported, export and have exported Licensed Products, including, without limitation, any Dimerizer included or utilized therein, in the Territory, for any and all uses within the Licensed Field during the Term, and to make, have made, use, import and export, in each case solely for research purposes, including pre-clinical IND-enabling toxicology and other pre-clinical studies, but not to conduct clinical trials with respect to or to obtain Regulatory Approval for, sell or commercialize, Licensed Products, including, without limitation, any Dimerizer included or utilized therein, for any indication other than the Primary Indications until the end of the Expansion Period and, if Licensee elects to add Additional Indications to the Licensed Field during the Expansion Period, for any indication other than the Primary Indications and the Additional Indications until the end of the Non-Cancer Expansion Period.

This agreement includes a non-exclusive grant back from Licensee to Licensor.

License Property
Licensor is the owner of or otherwise controls certain proprietary Licensed Patent Rights and Licensed Technology.

Licensors Dimerizer shall mean the compound known as xx1903, all analogs and derivatives of xx1903 and any Dimerizcr or salt thereof, where the composition of matter thereof or its use as a divalent ligand is, at any time during the Primary License Term, within the scope of a claim in any patent or patent application within the Licensed Patent Rights.

xx1903 is for the treatment of GvHD as an orphan drug.

GvHD shall mean a clinical condition involving acute or chronic adverse effects or symptoms resulting from the allogenic transplantation of bone marrow, hematopoietic or stem cells into a human being in which engrafted donor cells attack the patients organs and tissues which can be treated by activating cell signaling leading to apoptosis of the transplanted cells.

Cell Transplantation Indication shall mean GvHD or any other acute or chronic adverse clinical effect in a human being resulting from transplantation of bone marrow, hematopoietic or stem cells that can be treated by inducing apoptosis of transplanted cells, or in the case of a bone marrow, hematopoietic or stem cell product for transplantation that includes cells containing a gene coding for an Inducible Caspase, any disease or condition in a human being that can be treated by such product.

Licensed Products include  BPX-101 (formerly BP-GMAX-CDJ) , and, CaspaCIDe Donor Lymphocyte Infusion.

Field of Use
Licensed Field shall mean the treatment or prevention of the progression or occurrence in humans of any Primary Indication and/ or any Additional Indication, such as kidney cancer, or any noncancer indication, as the case may be.

Licensee is developing cell therapies to treat cancers and other chronic and life-threatening diseases.

IPSCIO Record ID: 383612

License Grant
Licensor grants an exclusive, even as to Licensor, except as required for Licensor to meet its development and supply obligations hereunder, right and license, with the right to sublicense, during the Term of this Agreement under the Licensor Intellectual Property and Licensors interest in any Joint Patent Rights and Joint Technology solely to research, develop, make, have made, use, sell, offer for sale and import Products in the Field in the Licensee Territory, and a non-exclusive right and license, with the right to sublicense, during the Term of this Agreement under the Licensor Intellectual Property to research, make, have made, use and export Products in the Field in North America.
License Property
Licensor is a stem cell therapeutic leader focused on developing and marketing products to treat medical conditions and possesses broad scientific and clinical leadership in the field of human mesenchymal stem cells (MSCs) and know-how, expertise and intellectual property rights pertaining to MSCs, including its Prochymal product and Chondrogen product.

Chondrogen shall mean any formulation, dosage form or delivery system that contains culturally expanded, undifferentiated, unmodified human MSCs for local delivery for the Articulating Orthopedic Indication and any Improvements thereto.

Prochymal shall mean any formulation, dosage form or delivery system suitable for Vascular Administration that contains culturally expanded, undifferentiated, unmodified human MSCs, and any Improvements thereto.

Ulcerative Colitis Indication shall mean the use of Prochymal for the treatment or prevention of ulcerative colitis.

Mesenchymal Stem Cells or MSCs shall mean the human formative pluripotential blast cells found inter alia in bone marrow, blood, dermis and periosteum that are capable of differentiating into any of the specific types of mesenchymal or connective tissues.

COPD Indication shall mean the use of Prochymal to treat chronic obstructive pulmonary disease.

Articulating Orthopedic Indication shall mean the use of Chondrogen for preventing or treating diseases, defects or conditions of articulating joints, including cartilage and meniscus repair, osteoarthritis, osteochondral defect repair, and the treatment of acute and chronic orthopedic pain within an articulating joint.

Crohns Indication shall mean the use of Prochymal to treat Crohns disease.

Diabetes Indication shall mean the use of Prochymal for the prevention or treatment of Type I diabetes.

GvHD Indication shall mean the use of Prochymal to treat or prevent graft versus host disease.

Cardiac Indication shall mean the use of Prochymal to treat or prevent acute myocardial infarction.

Pain Therapeutic shall mean use of Chondrogen for the mitigation or relief of orthopedic pain with a Statistically Significant duration of relief of at least one year.

Field of Use
Field shall mean with respect to Prochymal, all applications for the prevention or treatment of diseases, defects, or conditions in humans, and with respect to Chondrogen, the Articulating Orthopedic Indication.

IPSCIO Record ID: 26488

License Grant
The Licensor grants to the Licensee worldwide rights to Azacitidine, Vidaza.
License Property
Vidaza is the subject of a completed and published Phase III study indicating its safety and efficacy in the treatment of myelodysplastic syndromes, or MDS, a bone marrow disorder characterized by the production of abnormally functioning, immature blood cells.  The myelodysplastic syndromes are a diverse collection of hematological conditions united by ineffective production (or dysplasia) of myeloid blood cells and risk of transformation to acute myelogenous leukemia or AML.
Field of Use
The field of use relates to the medical industry.

IPSCIO Record ID: 369402

License Grant
University grants an exclusive license under Licensed Subject Matter to manufacture, have manufactured, use, import, offer to sell and/or sell Licensed Products within Licensed Territory for use within Licensed Field.

University grants an exclusive option to negotiate a worldwide, exclusive license to any Improvements made within two years of the effective date.

This agreement includes non-exclusive grant back to Licensor by Licensee.

License Property
The Licensed Subject Matter is
Novel Mechanistically Altered Tyrphostins with Potent Antitumor Activity, and,
Compounds for Treatment of Cell Proliferative Diseases.
Field of Use
The license is for a new class of cancer drugs called Degrasyns that is developed as anti-cancer agents.  The novel anti-cancer activity of these analogs relate to their ability to selectively degrade key proteins that are involved in tumor cell proliferation and survival.

Licensee is a biopharmaceutical company focused on the development of drugs to treat relapsed (re-occurrence of active disease) or refractory acute leukemia, multiple myeloma (an incurable blood cancer that invades and proliferates in bone marrow), and advanced carcinoid cancer patients.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.